NCOA3 and neoplasm: In collaboration with Drs. O’Malley and Lonard’s groups, we identified SI-2 as a potent SRC-3 inhibitor capable of decreasing SRC-3 protein levels and inhibiting breast cancer cell proliferation in vitro and tumor growth in vivo [14].